By: Mike Bassett From: medpagetoday.com The agents have significantly extended progression-free survival, but what are the options post-progression? The development and approval of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have been called game-changers in the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Treatment with these drugs — palbociclib, ribociclib, …
Improving Upon Treatment Standards in HR+ Breast Cancer
By: Nichole Tucker From: targetedonc.com In an interview with Targeted Oncology, Erica Mayer, MD, discussed advances in the treatment landscape of HR-positive, HER2-negative breast, primarily with endocrine therapy and CDK4/6 inhibition. Treatment of metastatic hormone receptor (HR)-positive, HER2-negative breast cancer is traditionally executed with the use of endocrine therapy. With the emergence of targeted therapies for the treatment of this disease, …